Company intelligence / Profile preview

IceCure Medical

Caesarea, Haifa District, Israelicecure-medical.com ↗

Ownership: Public · ICCM
Development stage: Commercial

Overview

IceCure Medical’s ProSense Cryoablation System uses liquid nitrogen to achieve ultra-cold temperatures that destroy tumor tissue in a minimally invasive procedure. Clinical studies have shown high efficacy, with interim results from the ICE3 trial reporting a recurrence-free rate of approximately 96.91% in breast tumor patients. The system has been adopted globally and supports both office-based and hospital procedures.

Therapeutic areas: Oncology
Modalities: Device
Industry: Therapeutic Medical Devices

Financials

Market cap: $4.8M
Total revenue: $907K
Enterprise value: $-7.1M

Beyond the preview

Go deeper on IceCure Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IceCure Medical.

Explore the full profile